Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

PURPOSE: B-cell leukemia/lymphoma-2 (BCL-2) overexpression is common in many non-Hodgkin lymphoma (NHL) subtypes. A phase I trial in patients with NHL was conducted to determine safety, pharmacokinetics, and efficacy of venetoclax, a selective, potent, orally bioavailable BCL-2 inhibitor. PATIENTS A...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Clin Oncol
Auteurs principaux: Davids, Matthew S., Roberts, Andrew W., Seymour, John F., Pagel, John M., Kahl, Brad S., Wierda, William G., Puvvada, Soham, Kipps, Thomas J., Anderson, Mary Ann, Salem, Ahmed Hamed, Dunbar, Martin, Zhu, Ming, Peale, Franklin, Ross, Jeremy A., Gressick, Lori, Desai, Monali, Kim, Su Young, Verdugo, Maria, Humerickhouse, Rod A., Gordon, Gary B., Gerecitano, John F.
Format: Artigo
Langue:Inglês
Publié: American Society of Clinical Oncology 2017
Sujets:
ORIGINAL REPORTS
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5455685/
https://ncbi.nlm.nih.gov/pubmed/28095146
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2016.70.4320
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires